Home
/
Phathom Pharmaceuticals, Inc.
/
Financials
/
Quarterly
Phathom Pharmaceuticals, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Phathom Pharmaceuticals, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$49.50M
Oct 30, 2025
Q2
2025
Jun 30, 2025
$39.50M
Aug 7, 2025
Q1
2025
Mar 31, 2025
$28.52M
May 1, 2025
Q3
2025
Sep 30, 2024
$16.35M
Oct 30, 2025
Q2
2025
Jun 30, 2024
$7.32M
Aug 7, 2025
Q1
2025
Mar 31, 2024
$1.91M
May 1, 2025
Q3
2024
Sep 30, 2023
$0
Nov 7, 2024
Q2
2024
Jun 30, 2023
$0
Aug 8, 2024
Q1
2024
Mar 31, 2023
$0
Jun 14, 2024
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($29.97M)
Oct 30, 2025
Q2
2025
Jun 30, 2025
($75.81M)
Aug 7, 2025
Q3
2025
Jun 30, 2025
($75.81M)
Oct 30, 2025
Q2
2025
Mar 31, 2025
($94.32M)
Aug 7, 2025
Q1
2025
Mar 31, 2025
($94.32M)
May 1, 2025
Q3
2025
Mar 31, 2025
($94.32M)
Oct 30, 2025
Q3
2025
Sep 30, 2024
($85.58M)
Oct 30, 2025
Q2
2025
Jun 30, 2024
($91.45M)
Aug 7, 2025
Q3
2025
Jun 30, 2024
($91.45M)
Oct 30, 2025
Q1
2025
Mar 31, 2024
($82.85M)
May 1, 2025
Q2
2025
Mar 31, 2024
($82.85M)
Aug 7, 2025
Q3
2025
Mar 31, 2024
($82.85M)
Oct 30, 2025
Q3
2024
Sep 30, 2023
($43.24M)
Nov 7, 2024
Q3
2024
Jun 30, 2023
($40.97M)
Nov 7, 2024
Q2
2024
Jun 30, 2023
($40.97M)
Aug 8, 2024
Q2
2024
Mar 31, 2023
($37.81M)
Aug 8, 2024
Q3
2024
Mar 31, 2023
($37.81M)
Nov 7, 2024
Q1
2024
Mar 31, 2023
($37.81M)
Jun 14, 2024
Q3
2023
Sep 30, 2022
($51.09M)
Nov 9, 2023
Q3
2023
Jun 30, 2022
($50.92M)
Nov 9, 2023
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($15.27M)
Oct 30, 2025
Q2
2025
Jun 30, 2025
($59.92M)
Aug 7, 2025
Q1
2025
Mar 31, 2025
($78.86M)
May 1, 2025
Q3
2025
Sep 30, 2024
($70.80M)
Oct 30, 2025
Q2
2025
Jun 30, 2024
($77.30M)
Aug 7, 2025
Q1
2025
Mar 31, 2024
($69.95M)
May 1, 2025
Q3
2024
Sep 30, 2023
($35.66M)
Nov 7, 2024
Q2
2024
Jun 30, 2023
($31.70M)
Aug 8, 2024
Q1
2024
Mar 31, 2023
($30.08M)
Jun 14, 2024
Q3
2023
Sep 30, 2022
($42.53M)
Nov 9, 2023
Q2
2023
Jun 30, 2022
($45.36M)
Aug 10, 2023
Q1
2023
Mar 31, 2022
($37.91M)
May 10, 2023
Q3
2022
Sep 30, 2021
($33.14M)
Nov 9, 2022
Q2
2022
Jun 30, 2021
($35.32M)
Aug 2, 2022
Q1
2022
Mar 31, 2021
($33.58M)
May 10, 2022
Q3
2021
Sep 30, 2020
($32.83M)
Nov 8, 2021
Q2
2021
Jun 30, 2020
($20.02M)
Aug 10, 2021
Q1
2021
Mar 31, 2020
($20.38M)
May 11, 2021
Q3
2020
Sep 30, 2019
($6.28M)
Nov 10, 2020
Q2
2020
Jun 30, 2019
($83.01M)
Aug 6, 2020